| Literature DB >> 35031056 |
Kyongje Sung1,2, Hanna Glazer1, Jessica O'Grady1, Mindy L McEntee1,3, Laura Bosley1, Dana Boatman Reich4, Barry Gordon1,5.
Abstract
BACKGROUND: Although visual abnormalities are considered common in individuals with autism spectrum disorders, the associated electrophysiological markers have remained elusive. One impediment has been that methodological challenges often preclude testing individuals with low-functioning autism (LFA).Entities:
Keywords: Autism; EEG alpha spectral power; Low-functioning autism; Visual evoked potentials
Year: 2022 PMID: 35031056 PMCID: PMC8759181 DOI: 10.1186/s40814-021-00960-7
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Participant Demographics
| Participant | Sex | Age (yrs) | Neuropsychological Testing | Speech-Language Abilities | Medications (daily dosage) |
|---|---|---|---|---|---|
| P1_LFA | M | 17 | ADOS Module 1 (composite score 21); PPVT-IV-B (score 20)† | Nonverbal | Vitamins; digestive enzymes |
| P2_LFA | M | 25 | ADOS Module 2 (composite score 23); KBIT-2 (composite IQ 44); PPVT-IV-B (score 36) | Minimally verbal | Risperidone (1mg); Cetirizine (10mg); Lithium (1500 mg) |
| P3_LFA | M | 39 | ADOS Module 4 (composite score 22); KBIT-2 (composite IQ 61); PPVT-IV-B (score 58) | Minimally verbal: single words only; monotonic | Sertraline (50mg), Clomipramine (50mg) |
| P4_LFA | M | 48 | ADOS Module 4 (composite score 19); KBIT-2 (composite IQ 112); PPVT-IV-B (score 94) | Minimally verbal: single words only; aversion to /pl/ and other speech sounds | Sertraline (100mg); Amlodipine (5mg) |
| P5_LFA | M | 28 | ADOS Module 4 (composite score 18); KBIT-2 (composite IQ 66); PPVT-IV-B (score 62) | Minimally verbal | Loratadine (10mg) |
| P6_LFA | F | 26 | ADOS Module 4 (composite score 19); KBIT-2 (composite IQ 64); PPVT-IV-B (score 45) | Minimally verbal | NA |
| P7_HFA | M | 26 | ADOS Module 4 (composite score 14); KBIT-2 (composite IQ 77); PPVT-IV-B (score 71) | Verbal | NA |
| P8_HFA | M | 26 | ADOS Module 4 (composite score 10); KBIT-2 (composite IQ 129); PPVT-IV-B (score 136) | Verbal | Duloxetine (30mg) |
| P9_HFA | F | 21 | ADOS Module 4 (composite score 14); KBIT-2 (composite IQ 80); PPVT-IV-B (score 88) | Verbal | NA |
| P10_HFA | M | 45 | ADOS Module 4 (composite score 10); KBIT-2 (composite IQ 144); PPVT-IV-B (score 137) | Verbal | Ropinirole (dosage undisclosed) |
| P11_HFA | M | 30 | ADOS Module 4 (composite score 10); KBIT-2 (composite IQ 89); PPVT-IV-B (score 98) | Verbal | NA |
| P12_HFA | M | 27 | ADOS Module 4 (composite score 18); KBIT-2 (composite IQ 103); PPVT-IV-B (score 116) | Verbal | Sertraline (200mg); Quetiapine (200mg) |
| P13_TD | M | 26 | NA | Verbal | NA |
| P14_TD | M | 25 | NA | Verbal | NA |
| P15_TD | M | 28 | NA | Verbal | NA |
| P16_TD | M | 22 | NA | Verbal | NA |
| P17_TD | F | 20 | NA | Verbal | NA |
| P18_TD | M | 35 | NA | Verbal | NA |
LFA: Low-Functioning Autism; HFA: High-functioning Autism; TD: Typical development. ADOS: Autism Diagnostic Observation Schedule (2nd ed); PPVT-III (standard score): Peabody Picture Vocabulary Test-III; PPVT-IV-B (standard score): Peabody Picture Vocabulary Test-IV-form B; KBIT-2: Kaufman Brief Intelligence Test-2; All tests were administered at the time of study participation
†KBIT-2 test was not administered
Fig. 1Visual evoked potential waveforms recorded from electrode Oz and averaged by participant group. LFA low-functioning autism, HFA high-functioning autism, TD typical development. Time is on the x-axis in milliseconds; amplitude is on the y-axis in microvolts. The three waveform components of the early cortical evoked response, P1-N1-P2, are labeled. The vertical line at 0 ms denotes stimulus onset
Visual evoked potential measurements for the three participant groups. Mean peak latencies (ms) and amplitudes (μV) are shown for the early P1-N1-P2 waveform components; standard deviations are in parentheses
| Group | P1 | N1 | P2 | |||
|---|---|---|---|---|---|---|
| LFA | 94.7 (±25.8) | 3.34 (±1.79) | 141.3 (±26.5) | -1.27 (±3.12) | 221.3 (±28.0) | 3.43 (±2.32) |
| HFA | 82.0 (±22.4) | 2.98 (±1.42) | 116.8 (±30.2) | -2.44 (±2.66) | 208.7 (±27.7) | 5.02 (±2.59) |
| TD | 78.7 (±8.2) | 1.94 (±1.92) | 115.3 (±16.1) | -1.95 (±3.46) | 192.0 (±26.4) | 5.23 (±2.19) |
LFA: Low-Functioning Autism. HFA: High-Functioning Autism. TD: Typical Development
Fig. 2Power spectrum (top panel), event-related spectral perturbation (middle panel), and the spectral density (bottom panel) of three groups at Oz. The time window interval was [−500ms, 500 ms] with the checkerboard onset at 0 ms, and the frequency band analyzed was 4–30 Hz. Two horizontal lines in the top and middle panel indicate the alpha band (8–13 Hz). Two vertical lines in the spectral density plots indicate the alpha band
Fig. 3Topographical maps showing the distribution of prestimulus (−500 to 0 ms) and poststimulus (4 to 500 ms) spectral power in the alpha and theta bands for the three participant groups. LFA low-functioning autism, HFA high-functioning autism, TD typical development. Spectral power is color-coded as shown in the color bar with red representing the highest level of spectral power and blue representing the lowest level of spectral power
Fig. 4Bar graph showing average prestimulus (shaded gray) and poststimulus alpha (left panel) and theta (right panel) power for the three participant groups. Error bars indicate the 95% bias-corrected bootstrapped (N=2000) confidence intervals